title: IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial.
abstract: OBJECTIVE
  To compare the IVF/ICSI outcomes of the long GnRH agonist and the fixed GnRH antagonist protocol in women with PCOS.
  
  
  METHODS
  Randomized controlled trial.
  
  
  METHODS
  Baskent University Department of Obstetrics and Gynecology.
  
  
  METHODS
  Three hundred women with PCOS.
  
  
  METHODS
  IVF/ICSI following the long GnRH agonist down-regulation or the fixed GnRH antagonist protocols.
  
  
  METHODS
  Ongoing pregnancy rates.
  
  
  RESULTS
  Ongoing pregnancy rates were 36.4 % in the OCP + GnRH agonist group and 35.9 % in the OCP + GnRH antagonist group (p > 0.05). Progesterone levels on the day of hCG (0.76 ± 0.71 vs. 0.58 ± 0.50), endometrial thickness on the day of hCG (11.57 ± 2.50 vs. 10.50 ± 2.01), total gonadotropin used (1388.71 ± 482.39 vs. 1253.25 ± 415.81), and duration of COH (9.07 ± 1.96 vs. 8.39 ± 1.75) were significantly lower in the OCP + GnRH antagonist group.
  
  
  CONCLUSIONS
  The OCP + long GnRH agonist and the OCP + fixed GnRH antagonist protocols yield similar ongoing pregnancy rates in women with PCOS. Although this study consisting three hundred patients, seems to be large enough in a single center, we were not able to reach to the actual size of power analysis which was approximately 3,000.
authors.affiliation: Division of Reproductive Endocrinology and IVF Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Sumer mah. 69168 sok. Grand Park Plaza C Blok kat:12 No:24 Seyhan, Adana, Turkey. bulenthaydar@yahoo.com
authors.forename: Bulent
authors.initials: B
authors.lastname: Haydardedeoglu
authors.forename: Esra Bulgan
authors.initials: EB
authors.lastname: Kilicdag
authors.forename: Ayse Huriye
authors.initials: AH
authors.lastname: Parlakgumus
authors.forename: Hulusi Bulent
authors.initials: HB
authors.lastname: Zeyneloglu
mesh_terms: D000328:Adult; D000736:Androstenes / Q000008:administration & dosage; D002985:Clinical Protocols; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage; D004997:Ethinyl Estradiol / Q000008:administration & dosage; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000037:antagonists & inhibitors*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D010062:Ovulation Induction / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000150:complications*; D011247:Pregnancy; D018873:Pregnancy Rate; D020554:Sperm Injections, Intracytoplasmic; D055815:Young Adult
chemical_list: D000736:Androstenes; D003277:Contraceptives, Oral, Combined; D007987:Gonadotropin-Releasing Hormone; D004997:Ethinyl Estradiol; C035144:drospirenone